235 related articles for article (PubMed ID: 30815688)
1. Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
Neira LF; Mantilla JC; Escobar P
J Antimicrob Chemother; 2019 Jun; 74(6):1634-1641. PubMed ID: 30815688
[TBL] [Abstract][Full Text] [Related]
2. Development and evaluation of novel miltefosine-polyphenol co-loaded second generation nano-transfersomes for the topical treatment of cutaneous leishmaniasis.
Dar MJ; McElroy CA; Khan MI; Satoskar AR; Khan GM
Expert Opin Drug Deliv; 2020 Jan; 17(1):97-110. PubMed ID: 31786952
[No Abstract] [Full Text] [Related]
3. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
4. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
[TBL] [Abstract][Full Text] [Related]
5. Topical formulations of miltefosine for cutaneous leishmaniasis in a BALB/c mouse model.
Van Bocxlaer K; Yardley V; Murdan S; Croft SL
J Pharm Pharmacol; 2016 Jul; 68(7):862-72. PubMed ID: 27230300
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
Trinconi CT; Reimão JQ; Coelho AC; Uliana SR
J Antimicrob Chemother; 2016 May; 71(5):1314-22. PubMed ID: 26851606
[TBL] [Abstract][Full Text] [Related]
7. Topical treatment of cutaneous leishmaniasis with novel amphotericin B-miltefosine co-incorporated second generation ultra-deformable liposomes.
Dar MJ; Khalid S; McElroy CA; Satoskar AR; Khan GM
Int J Pharm; 2020 Jan; 573():118900. PubMed ID: 31765786
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC
Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653
[TBL] [Abstract][Full Text] [Related]
9. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.
Aguiar MG; Pereira AM; Fernandes AP; Ferreira LA
Antimicrob Agents Chemother; 2010 Nov; 54(11):4699-704. PubMed ID: 20713665
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis.
Peixoto F; Nascimento MT; Costa R; Silva J; Renard G; Guimarães LH; Penna G; Barral-Netto M; Carvalho LP; Machado PRL; Carvalho EM
J Immunol Res; 2020; 2020():2789859. PubMed ID: 32851099
[TBL] [Abstract][Full Text] [Related]
11. Development of topical liposomes containing miltefosine for the treatment of Leishmania major infection in susceptible BALB/c mice.
Kavian Z; Alavizadeh SH; Golmohamadzadeh S; Badiee A; Khamesipour A; Jaafari MR
Acta Trop; 2019 Aug; 196():142-149. PubMed ID: 31103698
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of Miltefosine in Children and Adults with Cutaneous Leishmaniasis.
Castro MD; Gomez MA; Kip AE; Cossio A; Ortiz E; Navas A; Dorlo TP; Saravia NG
Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956421
[TBL] [Abstract][Full Text] [Related]
13. Miltefosine--discovery of the antileishmanial activity of phospholipid derivatives.
Croft SL; Engel J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S4-8. PubMed ID: 16904717
[TBL] [Abstract][Full Text] [Related]
14. A Luciferase-Expressing Leishmania braziliensis Line That Leads to Sustained Skin Lesions in BALB/c Mice and Allows Monitoring of Miltefosine Treatment Outcome.
Coelho AC; Oliveira JC; Espada CR; Reimão JQ; Trinconi CT; Uliana SR
PLoS Negl Trop Dis; 2016 May; 10(5):e0004660. PubMed ID: 27144739
[TBL] [Abstract][Full Text] [Related]
15. Investigation of anti-leishmanial efficacy of miltefosine and ketoconazole loaded on nanoniosomes.
Nazari-Vanani R; Vais RD; Sharifi F; Sattarahmady N; Karimian K; Motazedian MH; Heli H
Acta Trop; 2018 Sep; 185():69-76. PubMed ID: 29733808
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the efficacy of systemic miltefosine associated with photodynamic therapy with liposomal chloroaluminium phthalocyanine in the treatment of cutaneous leishmaniasis caused by Leishmania (L.) amazonensis in C57BL/6 mice.
Ribeiro JBP; Miranda-Vilela AL; Graziani D; Gomes MRA; Amorim AAS; Garcia RD; de Souza Filho J; Tedesco AC; Primo FL; Moreira JR; Lima AV; Sampaio RNR
Photodiagnosis Photodyn Ther; 2016 Mar; 13():282-290. PubMed ID: 26306406
[TBL] [Abstract][Full Text] [Related]
17. Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.
Carregal VM; Lanza JS; Souza DM; Islam A; Demicheli C; Fujiwara RT; Rivas L; Frézard F
Parasitol Res; 2019 Oct; 118(10):3077-3084. PubMed ID: 31401656
[TBL] [Abstract][Full Text] [Related]
18. The in vitro leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant Leishmania species of Brazil.
Morais-Teixeira Ed; Damasceno QS; Galuppo MK; Romanha AJ; Rabello A
Mem Inst Oswaldo Cruz; 2011 Jun; 106(4):475-8. PubMed ID: 21739037
[TBL] [Abstract][Full Text] [Related]
19. In Vitro and In Vivo Miltefosine Susceptibility of a Leishmania amazonensis Isolate from a Patient with Diffuse Cutaneous Leishmaniasis: Follow-Up.
Coelho AC; Trinconi CT; Costa CH; Uliana SR
PLoS Negl Trop Dis; 2016 Jul; 10(7):e0004720. PubMed ID: 27416021
[No Abstract] [Full Text] [Related]
20. In vivo antileishmanial efficacy of miltefosine against Leishmania (Leishmania) amazonensis.
García Bustos MF; Barrio A; Prieto GG; de Raspi EM; Cimino RO; Cardozo RM; Parada LA; Yeo M; Soto J; Uncos DA; Parodi C; Basombrío MA
J Parasitol; 2014 Dec; 100(6):840-7. PubMed ID: 25014108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
